IO Biotech share are trading higher after announced promising data from the Phase 2 basket trial of IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, in combination with Merck's anti-PD-1 therapy KEYTRUDA at the 2024 ESMO Congress.
Portfolio Pulse from Benzinga Newsdesk
IO Biotech shares rise following positive Phase 2 trial results of their cancer vaccine candidate IO102-IO103, in combination with Merck's KEYTRUDA, presented at the 2024 ESMO Congress.
September 16, 2024 | 11:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IO Biotech shares are trading higher after announcing promising data from a Phase 2 trial of their cancer vaccine candidate IO102-IO103, in combination with Merck's KEYTRUDA.
The announcement of positive trial results is a significant milestone for IO Biotech, likely boosting investor confidence and driving the stock price up. The combination with Merck's KEYTRUDA, a well-known therapy, adds credibility and potential market interest.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100